Opioid-like peptides and ghrelin mitigation of bariatric results depends on obesity level by Dyaczyński, Michał et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
ISSN: 0423-104X
e-ISSN: 2299-8306
Opioid-like peptides and ghrelin mitigation of sleeve
gastrectomy results depends on obesity level
Authors:  Michał Dyaczyński, Colin G Scanes, Marek Drożdż, Leontyna Wylężek,
Anna Rzepa, Andrzej Cieśla, Krystyna Pierzchała-Koziec
DOI: 10.5603/EP.a2019.0044
Article type: Original papers
Submitted: 2019-07-31
Accepted: 2019-09-12
Published online: 2019-09-30
This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
Articles in "Endokrynologia Polska" are listed in PubMed.
The final version may contain major or minor changes. 
Powered by TCPDF (www.tcpdf.org)
1 
 
Opioid-like peptides and ghrelin mitigation of bariatric results depend on obesity level 
Running title: Opioids and ghrelin affect bariatrics 
 
10.5603/EP.a2019.0044 
Michał Dyaczyński1, Marek Drożdż1, Leontyna Wylężek1, Colin G. Scanes2, Anna Rzepa3, 
Andrzej Cieśla4, Krystyna Pierzchała-Koziec5 
 
1Municipal Hospital, Siemianowice Śląskie, Poland 
2Colin G. Scanes: Center in Excellence in Poultry Science, University of Arkansas, Fayetteville, 
AR, United States 
32nd Department of General Surgery, Jagiellonian University Medical College, Krakow, Poland 
4Institute of Experimental and Clinical Medicine, Faculty of Medicine, University of Rzeszow, 
Poland 
5Department of Animal Physiology and Endocrinology, University of Agriculture in Krakow, 
Krakow, Poland 
 
 
Corresponence to: Krystyna Pierzchała-Koziec, Katedra Fizjologii i Endokrynologii Zwierząt, 
Uniwersytet Rolniczy w Krakowie, Al. Mickiewicza 24/28, 30–059 Kraków, tel: (+48) 
698 630 42; e-mail: rzkoziec@cyf-kr.edu.pl 
 
Abstract 
Introduction: Bariatric surgery, as the only effective treatment of obesity, has strong effects 
on the metabolism, and nervous and endocrine systems. Thus, based on the different opinions 
about the efficaciousness of morbid obesity treatments, the aim of the present study was to 
estimate the association of serum ghrelin and Met-enkephalin (native, five amino acids and 
cryptic, precursor of enkephalin) concentrations with body mass index (BMI) value in bariatric 
patients within 30 postoperative days. 
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Material and methods: The study was performed on 38 female patients divided into two 
groups: I — BMI lower than 40 kg/m2 (n = 18) and II — BMI higher than 40 kg/m2 (n = 20). 
Blood was taken before (–24 h), and 72 h and 30 days after the sleeve gastrectomy. Routine 
haematological, anthropometric, and metabolic parameters as well as thyroid-stimulating 
hormone (TSH), ghrelin, and Met-enkephalin values were measured in all patients.  
Results: There were statistically significant differences between the two groups before the 
surgery in terms of TSH, both forms of Met-enkephalin, triglyceride concentrations, and 
activity of alanine transaminase (ALT), gamma-glutamyltransferase (GGTP), and C-reactive 
protein (CRP). After 72 h, the serum levels of cryptic Met-enkephalin and CRP, and activity of 
enzymes varied between the two groups of patients. Thirty days after the surgery, some 
metabolic and immune parameters were still different in both female groups in favour of 
patients with lover BMI. However, significant differences were noticed in the levels of ghrelin 
(increase), and native (decrease) and cryptic Met-enkephalins (increase). 
Conclusions: The activity of endogenous peptides in bariatric patients is connected with the 
degree of obesity. Ghrelin level increases are negatively correlated with native Met-enkephalin 
changes shortly after bariatric surgery. The interplay of ghrelin and opioids might be considered 
as a predictor of postoperative weight loss success. 
Key words: opioids; ghrelin; obesity; bariatric surgery 
 
Introduction 
Obesity is a highly prevalent disease in the world, and it is caused by many different factors: an 
excess of nutrients, genetic background, lack of physical exercise, or disorder of the 
hypothalamo-gastrointestinal axis activity [1, 2]. Obesity is frequently subdivided into 
categories depending on a body mass index (BMI) value: class 1: BMI of 30 to < 35 kg/m2; 
class 2: BMI of 35 to < 40 kg/m2; and class 3: BMI of 40 kg/m2 or higher. Class 3 obesity is 
sometimes categorised as “extreme” or “severe/morbid” obesity [2, 3]. In spite of many 
scientific studies the borders between the three classes of obesity are inconsistent, and widely 
used parameters are not able to indicate the reason/reasons for progressive obesity. 
Currently, it may be concluded that the only effective treatment of obesity remains surgery. 
However, it must be pointed out that bariatric surgery has strong effects on the metabolism, and 
on the nervous and hormonal systems [3], because hunger and satiety are mediated by an 
interplay of nervous and endocrine signals at the central and peripheral levels [4]. Also, it is not 
clear why many patients are losing weight very slowly or even regaining the weight in a short 
time. 
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Since 2002 ghrelin has been considered as an important hormone stimulating the appetite in 
healthy mammals [5]; its effects have been correlated with the changes in synthesis, secretion, 
and concentration of opioid peptides in the blood, brain structures, and peripheral tissues in 
animals [6–8], which indicates a close relationship between these hormones.  
Endogenous opioid peptides are expressed in the central nervous system, and in peripheral 
tissues, mainly the gastrointestinal tract, adrenals, heart, and pancreas [9]. Met-enkephalin, the 
most widely occurring opioid, exists in the blood and in the tissues as a native, five-amino-acid 
peptide with short half-life (less than 1 min) and in a larger form called cryptic Met-enkephalin 
(PENK). The ratio of cryptic/native Met-enkephalin significantly varies in animal models 
depending on tissue, physiological status, stress, and gender [10–12]. The synthesis of 
enkephalins, in all structures of the digestive tract and in the areas of the hypothalamus, 
responsible for regulation of feeding behaviour, provides evidence of the involvement of these 
peptides in the regulation of nutrition [13]. The orexigenic effect of enkephalins has been 
proposed by some investigators, which suggest that endogenous opioid peptides and their 
specific receptors could be considered as effective targets for counteracting obesity [14, 15]. 
Thus, based on the different opinions on the efficacy of morbid obesity treatments, the aim of 
the present study was to estimate the impact of the degree of obesity on the roles of ghrelin and 
Met-enkephalin in the short-term mitigation of bariatric surgery effects. 
 
Material and methods 
Bariatric surgeries — sleeve gastrectomy — were performed in the Municipal Hospital in 
Siemianowice Śląskie. Each patient signed an informed consent form. The reported 
investigations were carried out in accordance with the principles of the Declaration of Helsinki. 
Anthropometric parameters (Tab. I) were measured in 38 qualified patients (age x = 30.4 years). 
Patients were divided into two groups: with BMI lower than 40 kg/m2 (x = 35.8 ± 3.4, n = 18) 
and with BMI higher than 40 kg/m2 (x = 46.1±5.2, n = 20). 
Blood samples were collected after overnight fasting: 24 h before and 72 h and 30 days after 
the surgery. 
The serum level of thyroid-stimulating hormone (TSH) was measured by the ELISA method. 
Ghrelin and Met-enkephalin levels in the blood were estimated by radioimmunoassay method 
(ghrelin-Phoenix Pharmaceuticals, Belmont, California, USA) and the method developed by 
Pierzchala and VanLoon for enkephalins [9]. Measurements of peptides were performed in the 
Department of Animal Physiology and Endocrinology at the University of Agriculture in 
Krakow. 
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The remaining parameters were estimated by the routine methods used in the hospital. For the 
normal range for all measurements the cut-offs for adult patients were used according to Synevo 
Laboratories. 
 
Statistical analysis 
Statistical analyses were performed by one-way ANOVA for multiple comparisons, or unpaired 
t-test to compare two mean values (Statistica 10 software StatSoft, USA). All data are expressed 
as means ± SEM. A value of p < 0.05 was considered statistically significant. 
 
Results 
Characteristics of parameters measured before the bariatric surgery are presented in Tables I–
III. There were statistically significant differences (p < 0.05) between two groups in term of 
TSH concentration, triglycerides, activity of alanine transaminase (ALT) and gamma-
glutamyltransferase (GGTP), and C-reactive protein (CRP). 
Statistical differences were observed after 72 h (Tab. III) in the activity of ALT, GGTP, and 
white blood counts cells (WBC) counts. The serum level of CRP (Tab. III) was dramatically 
elevated in the group with BMI < 40 kg/m2 (18 times), and it was a much higher increase than 
in the patients from the group with BMI > 40 kg/m2 (9 times, p < 0.05).  
Thirty days after the bariatric surgery (Tab. II) changes of total cholesterol, LDL, and 
triglycerides were observed in both groups. Significant differences (Tab. III) were also observed 
in the activity of ALT, prolonged higher WBC, and high serum level of CRP. 
The native Met-enkephalin level in the group with BMI < 40 kg/m2 was significantly lower (p 
< 0.05) than in the blood of patients with BMI > 40 kg/m2 at each measured point (Fig. 1) Blood 
levels of opioids measured three days after bariatric surgery were decreased in both groups by 
~50% (p < 0.05). Thirty days after bariatric surgery Met-enkephalin levels increased but still 
were lower than before the operation in patients of both groups (p < 0.05). 
The changes of cryptic Met-enkephalin (Fig. 2) in patients with BMI < 40 kg/m2 had biphasic 
profile: decrease after three days by 21% (p < 0.05) and then increase after 30 days (p < 0.05). 
In contrast, cryptic Met-enkephalin level in the blood of females with elevated BMI, was much 
higher at –24 h (by 68%) and at +72 h (by 118%) than that seen in the second group (p < 0.05). 
After 30 days, the cryptic form of opioid was increased in this group to 17.1 ± 1.9 pmol/mL. 
The differences in the changes of both enkephalin forms are clearly seen in Fig. 3. The ratio of 
cryptic/native Met-enkephalin changed from 11.9 (–24 h) to 17.8 (+73 h) and to 43.7 (30 days) 
in the blood of females with BMI < 40 kg/m2. In the plasma of patients with BMI > 40 kg/m2 
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the ratio of cryptic/native enkephalins changed from 12.5 to 31.7 and to 25.9, respectively, at 
first, second, and third blood collection. 
Blood levels of ghrelin (Fig. 4) were very similar in both patient groups before surgery. Three 
days after bariatric procedure the ghrelin level was increased by a comparable degree in all 
patients (35–45%, p < 0.05). After 30 days, the blood level of ghrelin in the patients with lower 
BMI was elevated to 43.8 ± 4.6 fmol/mL (p < 0.05). Unexpectedly, patients with BMI > 40 
kg/m2 manifested significantly higher increase of plasma ghrelin level up to 52.8+5.7 fmol/mL 
(p < 0.05). 
 
Discussion  
Obesity is connected with many changes of metabolic parameters. Qualification of patients for 
bariatric surgery must consider the lipid and carbohydrate panels and liver enzyme activity [16]. 
Analysis of triglycerides showed differences between the two groups of patients. Caution 
should be exercised in patients with BMI > 40 kg/m2 and with significantly higher level of CRP 
even 30 days after bariatric surgery. 
Accumulating evidence indicates that a state of chronic inflammation plays a crucial role in the 
pathogenesis of obesity-related metabolic dysfunction. Some data show that high BMI is 
connected with elevated CRP in obese patients. Bariatric surgery causes a significant decrease 
in the inflammation process, which is closely associated with adipose tissue loss. Santos et al. 
found that three months after gastric banding surgery CRP was significantly decreased together 
with weight loss, increased iron absorption, and decreased triglyceride activity [17]. The present 
results indicate that significantly elevated CRP level in the blood of patients with BMI > 40 
may be the effect of much slower body weight loss during the first 30 days after bariatric 
surgery. 
In spite of the fact that the TSH level was within the reference range, the present study showed 
a positive correlation between the lower TSH level (1.74 ± 0.11 µIU/mL) and BMI below 40 
as well as between the higher TSH level (2.43 ± 0.30 µIU/mL) and BMI above 40. Interestingly, 
higher TSH level was positively correlated with increased levels of ALT, GGTP, CRP, and 
triglycerides, clearly confirming that morbid obesity is connected with decreased energy 
expenditure by diminishing the degree/intensity of thyroid functions and metabolic processes 
[18].  
It was noted that higher levels of TSH positively correlated with elevated concentrations of 
lipids [19]. In terms of metabolic syndrome prevention, some scientists suggest monitoring the 
TSH and thyroid hormones in overweight and obese children [19] and adolescents [20]. 
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Bariatric surgeries have a strong impact on the metabolism, carbohydrates, and lipid turnover 
as well as on the hormonal system [3, 21, 22]. 
Endogenous opioid peptides are synthesised in all parts of the gastrointestinal tract, so each 
bariatric surgery has a strong impact on the enkephalin concentration and activity of the brain–
gastrointestinal axis.  
Some studies have suggested that endogenous opioids play a role in regulating consummatory 
behaviour and weight gain during access to palatable diets [15, 23]. Such results are interesting 
when viewed in the context of human genetic screens, strongly implicating opioid receptors in 
obesity phenotypes [24]. Additionally, antagonism of opioid receptors can in some 
circumstances be effective for reversing such phenotypes in preclinical and clinical studies. A 
previous study of our group showed that in obese human and animal experimental models 
(piglet, mouse) blood and tissue concentrations of Met-enkephalin were higher than in lean 
controls (unpublished data). In the present study, blood native Met-enkephalin levels were 
higher in females with BMI > 40 before and after bariatric surgery compared to values observed 
in patients with BMI < 40. Interestingly, native Met-enkephalin was decreased three days after 
the surgery in both groups of patients by 58% (BMI > 40) and 45% (BMI < 40) but at 30 days 
started to grow slowly; however, they were still lower than before the surgery. It may be 
suggested that the gastrointestinal tract is one of the main sources of enkephalin-releasing 
PENK and/or native forms to the peripheral blood [9]. On the other hand, during the 30 days, 
the native form of endogenous opioid peptides was probably released from other sources — 
adrenals, vagal nerve, pancreas or blood proteins — so its level increased. Bariatric surgery is 
also stressful for the patients and activates the hypothalamic-pituitary-adrenal axis. Increased 
release of corticoliberin from the hypothalamus stimulated synthesis and release of the 
adrenocorticotrophin from proopiomelanocortin. Paradoxically, proopiomelanocortin (POMC), 
the anorexigenic regulator of food uptake, is the precursor of enkephalins, which stimulate food 
intake [3].  
Native Met-enkephalin is hydrolysed by specific aminopeptidases from the larger forms of 
peptide, called cryptic form or proenkephalin (PENK), which are present in tissues and blood 
proteins [9]. It seems probable that an alternative source of cryptic Met-enkephalin was more 
active in patients with lower BMI than in those with morbid obesity. Figure 2 clearly shows 
that the concentration of proenkephalin was increased 30 days after the bariatric surgery. The 
question arises as to why the cryptic form was not enzymatically processed to the native Met-
enkephalin. It can be speculated that the aminopeptidase activity was diminished due to 
disturbed synthesis after bariatric surgery. Trying to prove this hypothesis we analysed the 
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cryptic/native Met-enkephalin ratio, which was extremely increased at the end of the study in 
the group with lower BMI. Unexpectedly, the ratio was lower in the patients with higher BMI 
parallel with lower level of PENK and elevated concentration of native Met-enkephalin. These 
results clearly showed the differences in the metabolic processes, enzyme activity, and hormone 
concentrations dependent on the class of obesity. 
Interestingly, the varied concentrations of opioid peptides were negatively correlated with 
ghrelin level 30 days after bariatric surgery. 
Ghrelin levels in female patients from both studied groups were lower than those presented in 
previous research on non-obese humans [25]. After the bariatric surgery, blood ghrelin 
concentrations were increased dependently of the BMI levels: by 91% in the group with lower 
BMI and by 131% in the patients from group with higher BMI (p < 0.05). These changes were 
simultaneous with the decreased levels of native and elevated cryptic forms of enkephalin. 
Ghrelin levels rise with prolonged fasting and fall after a meal; therefore, weight loss via calorie 
restriction increases ghrelin levels, which may contribute to the poor long-term efficacy of 
dietary manipulation to control obesity. The short- and long-term effects of bariatric surgery 
upon ghrelin levels are still unclear; different bariatric procedures appear to have variable 
effects upon ghrelin secretion [3]. Interestingly, sleeve gastrectomy may decrease circulating 
acylated ghrelin concentrations, possibly due to the removal of ghrelin-producing cells in the 
stomach [3]. Ghrelin blood levels in obese individuals are much lower than in healthy humans, 
probably due to reducing the hormone transport into the brain [26] or ghrelin resistance [27]. 
Diet-induced weight loss increases ghrelin levels, which may be a barrier to sustaining long-
term weight loss [28]. Ghrelin acts via the growth hormone secretagogue receptor 1A (GHSR-
1A), a G-coupled receptor expressed in the brain and peripheral tissues [7]. Cabral et al. [28] 
showed that centrally administered ghrelin reaches and increases c-Fos levels in many brain 
areas with expressed GHSR-1A. They also found that peripheral ghrelin mainly reaches and 
activates brain areas that are close to circumventricular organs, allowing transportation of the 
circulating hormone to the brain. These results are in line with the findings of Banks [29], i.e. 
limited ghrelin brain accessibility is because its transport across the blood–brain barrier (BBB) 
in the brain-to-blood direction is by a saturable system, but blood-to-brain influx is very low. It 
has also been shown that the transportation of ghrelin to the brain was lower in obese individuals 
[29]. 
Holst et al. [30] found that GHSR-1A can act in a ghrelin-independent manner because this 
receptor is able to bind other ligands and heterodimerise with other G-protein-coupled receptors 
in order to modulate their activity. 
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GHSR-1A receptor, originally known as “orphan” receptor, stimulates growth hormone 
secretion and binds other growth hormone-releasing peptides (GHRP), e.g. Met-enkephalin and 
GHRP-6 [31]. Taken together, because the present study shows that in obese females the blood 
level of Met-enkephalin was elevated in parallel with decreased level of ghrelin, it can be 
postulated that these hormones interact in the regulation of appetite probably through the same 
receptor/receptors. However, question arises whether the enkephalin-ghrelin system, in spite of 
its orexigenic effect, will be a potential pharmacological target for new compounds regulating 
appetite in patients after bariatric surgery [32]. Future research must consider not only the role 
of ghrelin and opioid peptides, but also their impact on physiological, psychological, and 
genetic factors in weight loss failure or recidivism after bariatric surgery. 
 
Conclusions: 
1. The activity of endogenous peptides in bariatric patients is connected with the degree of 
obesity.  
2. Ghrelin level increases are negatively correlated with native Met-enkephalin changes shortly 
after bariatric surgery. 
3. The interplay of ghrelin and opioids might be considered as a predictor of postoperative 
weight loss success. 
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Table I. Characteristics of parameters measured before bariatric surgery  
Parameter BMI < 40 kg/m2 BMI > 40 kg/m2 
Number of patients  
(female) 
18 20 
BMI [kg/m2] 35.9 ± 3.4 46.1 ± 5.2* 
Waist circumferences [cm] (min–max) 115 (83–144) 126 (104–146) 
Hip circumferences [cm] (min–max) 129 (110–145) 134 (110–160) 
Blood pressure [mm Hg] 
(systolic/diastolic) 
144/98 142/91 
HbA1c (%) 5.4 ± 0.3 5.8 ± 0.4 
Fe [mmol/L] 16.14 ± 1.8 13.27 ± 1.4 
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Ca [mmol/L] 2.09 ± 0.2 2.43 ± 0.2 
B12 [pmol/L] 318.5 ± 21 377.3 ± 33 
TSH [μIU/mL] 1.74 ± 0.1 2.43 ± 0.3* 
–24 h, X ± SE, *p < 0.05 between BMI. BMI — body mass index; HbA1c — glycated 
haemoglobin; Fe — iron; Ca — calcium; TSH — thyroid-stimulating hormone; SE — standard 
error 
 
Table II. Comparison of parameters measured before and 30 days after bariatric surgery  
Time   
BMI [kg/m2] 
Before (–24 h) 
 
After (30 days) 
 Parameter   
Total cholesterol 
[mmol/L] 
< 40 
> 40 
5.36 ± 0.1 
5.61 ± 0.2 
4.07 ± 0.1a 
4.81 ± 0.2* 
HDL [mmol/L] < 40 
> 40 
1.58 ± 0.05 
1.43 ± 0.07 
1.34 ± 0.03 
1.42 ± 0.02 
LDL [mmol/L] < 40 
> 40 
3.3 ± 0.1 
3.5 ± 0.2 
2.0 ± 0.1a 
2.8 ± 0.2* 
Triglycerides 
[mmol/L] 
< 40 
> 40 
1.30 ± 0.1 
1.60 ± 0.1* 
1.22 ± 0.08 
1.68 ± 0.1* 
Creatinine [μmol/L] < 40 
> 40 
60.0 ± 3.1 
68.1 ± 2.0 
67.0 ± 3.3 
68.1 ± 4.2 
–24 h vs. 30 days, X ± SE, *p < 0.05 between BMI groups, ap < 0.05 between –24 h and 30 
days); BMI — body mass index; HDL — high density lipoprotein; LDL — low density 
lipoprotein; SE — standard error 
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Table III. Characteristic of parameters measured before (–24 h), 72 hours (+72 h) and 30 days 
(+30 days) after the bariatric surgery  
Time   
BMI [kg/m2] 
-24 h +72 h + 30 days 
Parameter  
ALT [U/L] < 40 
> 40 
21.1 ± 1.1 
31.0 ± 2.3* 
26.1 ± 1.3 
38.3 ± 2.1*a 
33.3 ± 1.9a 
41.6 ± 2.3*a 
GGTP [U/L] < 40 
> 40 
28.7 ± 1.2 
36.1 ± 1.8* 
35.5 ± 3.1a 
23.1 ± 2.4*a 
26.8 ± 1.9 
32.2 ± 2.1 
Glucose 
[mmol/L] 
< 40 
> 40 
5.01 ± 0.30 
5.95 ± 0.50 
4.92 ± 0.20 
5.66 ± 0.40 
5.49 ± 0.60 
5.76 ± 0.70 
Haemoglobin 
[mmol/L] 
< 40 
> 40 
8.25 ± 0.9 
8.62 ± 1.1 
7.38 ± 0.8 
7.38 ± 0.9 
7.94 ± 1.4 
8.49 ± 1.5 
WBC 
x 109/L 
< 40 
> 40 
7.01 ± 0.8 
8.70 ± 1.2 
9.55 ± 1.2 a 
11.20 ± 1.3a 
8.82 ± 1.1a 
7.36 ± 0.9 
CRP [mg/L] < 40 
> 40 
7.01 ± 0.8 
8.70 ± 1.2* 
129.7 ± 10.3a 
78.5 ± 8.7 *a 
5.3 ± 0.4 
6.2 ± 0.4b 
X ± SE, *p < 0.05 between BMI groups, a,bp < 0.05 between –24 h, +72 h, and 30 days; BMI 
— body mass index; ALT — alanine transaminase; GGTP — gamma-glutamyltransferase; 
CRP — C-reactive protein; WBC — white blood counts cells; SE — standard error 
 
Figure 1. Blood native Met-enkephalin levels [pmol/mL] in females before (0, –24 h) and after 
bariatric surgery (3 days, +72 h) and 30 days (x ± SEM, *p < 0.05 between BMI < 40 and BMI 
> 40 kg/m2, different letter superscripts a,b p < 0.05 show the significant difference between 
results obtained at 0, 3 and 30 days in both BMI groups). BMI — body mass index; SEM — 
standard error of the mean 
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Figure 2. Blood cryptic Met-enkephalin levels [pmol/mL] in females before (0, –24 h) and after 
bariatric surgery (3 days, +72 h) and 30 days (x ± SEM, *p < 0.05 between BMI < 40 and BMI 
> 40 kg/m2, different letter superscripts a,b p < 0.05 show significant difference between results 
obtained at 0, 3 and 30 days in both BMI groups). BMI — body mass index; SEM — 
standard error of the mean 
 
Figure 3. Cryptic/native Met-enkephalin ratio values in females before (0, -24 h) and after 
bariatric surgery (3 days, +72 h) and 30 days (x ± SEM, *p < 0.05 between BMI < 40 and BMI 
> 40 kg/m2, different letter superscripts a,b p < 0.05 show significant difference between results 
obtained at 0, 3 and 30 days in both BMI groups). BMI — body mass index; SEM — 
standard error of the mean 
 
Figure 4. Blood ghrelin levels [fmol/mL] in females before (0, –24 h) and after bariatric surgery 
(3 days, +72 h) and 30 days (x ± SEM, *p < 0.05 between BMI < 40 and BMI > 40 kg/m2, 
different letter superscripts a,b p < 0.05 show significant differences between between results 
obtained at 0, 3 and 30 days in both BMI groups). BMI — body mass index; SEM — 
standard error of the mean 
 
Figures description 
Fig. 1. Blood native Met-enkephalin levels in females before (0, -24h) and after  bariatric 
surgery  (3 days, +72 h) and 30 days (pmol/ml, x±SEM, *P<0.05 between BMI <40 and 
BMI>40 kg/m2, different letter superscripts a,bP<0.05 show significant differences between 
results obtained at 0,3 and 30 days in both BMI groups. 
 
Fig. 2. Blood cryptic Met-enkephalin levels in females before (0, -24h) and after  bariatric 
surgery  (3 days, +72 h) and 30 days (pmol/ml, x±SEM, *P<0.05 between BMI <40 and 
BMI>40 kg/m2, different letter superscripts a,bP<0.05 show significant differences between 
results obtained at 0,3 and 30 days in both BMI groups. 
 
Fig. 3. Cryptic/native  Met-enkephalin ratio values in females before (0, -24h) and after  
bariatric surgery  (3 days, +72 h) and 30 days (x±SEM, *P<0.05 between BMI <40 and 
BMI>40 kg/m2, different letter superscripts a,bP<0.05 show significant differences between 
results obtained at 0,3 and 30 days in both BMI groups. 
 
Fig. 4. Blood ghrelin levels in females before (0, -24h) and after  bariatric surgery  (3 days, 
+72 h) and 30 days (fmol/ml, x±SEM, *P<0.05 between BMI <40 and BMI>40 kg/m2, 
different letter superscripts a,bP<0.05 show significant differences between results obtained at 
0,3 and 30 days in both BMI groups. 
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